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Abstract
Background: Desmodium gangeticum (L.)DC., which belongs to the Leguminosae family, has been used in Taiwan and
other subtropical countries as an external medicine to remove blood stasis, activate blood circulation, and reduce
inﬂammation. It has been reported to have antioxidant effects and improve inﬂammatory responses in rats stimulated by
pro-inﬂammatory agents and induced gastric ulcers in experimental animals over the past few decades. This plant has
also been used to treat parasitic infections, but there are no reports regarding its effects on lung cancer. Therefore, this
study attempted to investigate its water crude extract (in abbreviation DG) on lung cancer cells.
Methods: A549 human lung cancer cells were tested for survival using MTT, trypan blue, and propidium iodide. The
effects of various concentrations of the crude extract of D. gangeticum (DG) (0.125~1 mg/ml) on the cell cycle and
apoptosis of A549 cells were analyzed by ﬂow cytometry and Western blotting methods.
Results: DG can inhibit the growth of A549 human lung cancer cells in a concentration- and time-dependent manner.
DG arrested A549 cells in the G1 phase by increasing the proteins expression of p21, p27, cyclin D1, and cyclin E.
Additionally, DG decreased the expression of cyclin A, B1, and Cdc 2 (CDK1) proteins.
Conclusions: DG demonstrated the anti-lung cancer activity by arresting the cell cycle in G1 via increasing the p21, p27,
cyclin D1, cyclin E, and decreasing Cdc2, cyclin A, and B1 proteins expression in A549 human lung cancer cells.
Keywords: Desmodium gangeticum (L.) DC., Anti-lung cancer, A549 human lung cancer cells, Cell cycle arrest, G1,
Apoptosis

1. Introduction

I

n Taiwan, cancer has been the number one killer
of the top ten causes of death for the past 39
years, and lung cancer ranks ﬁrst in mortality rate
[1]. According to the 2021 cancer statistics in the
United States, lung cancer also has the highest
mortality rate among all cancers [2]. In recent years,
the main treatment strategies for lung cancer are
surgery, chemotherapy, radiation therapy, or combined therapy, but the original problems still cannot
be solved entirely. For the past years, the research
and development of botanical drugs have increased

globally. For example, paclitaxel (Paclitaxel® or
Docetaxel®), commonly used to treat lung cancer, is
an active ingredient extracted from natural plants
[3]. Herbal medicines for anti-cancer are often found
to have antioxidant, anti-inﬂammatory, anti-bacterial, or anti-viral effects. In the case of limited
western medicine treatment for many diseases,
adjuvant therapy such as herbal medicine often has
a speciﬁc effect; in addition to current chemotherapy, Chinese herbal medicine may have a
reference value for lung cancer [4]. Therefore, this
study aimed to explore some herbal plants in Taiwan
that have inhibitory effects on lung cancer cells.
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Desmodium gangeticu (L.) DC. is a low-altitude
shrub plant growing in the middle and southern
Taiwan. Its water crude extract is referred to as DG.
The chemical composition of this plant has been
studied [5,6]. A series of studies [7,8] discussed its
pharmacological activity in experimental animals in
alcohol-, histamine-, and aspirin-induced gastric
ulcers; DG played a role in cell protection and
reducing gastric acid secretion in peptic ulcers [9].
DG improved learning and memory defects in
scopolamine-induced memory loss [10].
Additionally, it regulated blood sugar levels via
increasing insulin secretion, lowering cholesterol
and triglycerides, and increasing HDL [11]. The
anti-inﬂammatory and analgesic effects of DG also
have been reported [12,13]. Follow-up research
showed DG inhibited viability on various cancer
cells, especially on A549 human lung adenocarcinoma cells, and the effect was concentration- and
time-dependent. Therefore, this study attempted to
explore further the pharmacological activity and
mechanism of its anti-lung cancer effect.
Normal human cells have double sets of DNA, but
some cancer cells may have incomplete or multiple
sets of DNA due to abnormal differentiation [14]. By
measuring the content of DNA in cells, it is possible
to understand the distribution of the cell cycle and
understand the effect of drugs on the damage
caused by the drugs on the cancer cells when they
are processed on the cells [15]. The cell cycle can be
mainly divided into several stages: Gap 0 (G0)
phase, Gap 1 (G1) phase, Synthesis (S) phase, Gap 2
(G2) phase, and Mitosis (M) stage. The cell cycle
regulation has a rigorous control mechanism, in
which the substances that promote the cell cycle are
responsible for the cyclin-dependent kinases (CDK)
group. CDK is usually not activated and requires the
presence and combination of cyclin. After the two
form a cyclin/CDK complex, the cell can be
advanced from this state to the next state. Different
cyclins are produced at speciﬁc times in the cell
cycle and then broken down at speciﬁc times [16].
Cyclin D stimulates resting cells (G0), entering the
G1 phase. Mammals have three types of cyclin D:
cyclin D1, D2, and D3. When cyclin D binds to
CDK4/6 [17,18], the activated cyclin D/CDK4/6
complex, in turn, activates retinoblastoma (RB) protein [19]. Cyclin E binds to CDK2 following activation of cyclin D/CDK; when the cyclin E/CDK2
complex is activated, it promotes the G1 phase to the
S phase [20,21]. After the cell enters the S phase,
cyclin E is decomposed. CDK2 is released and
combined with cyclin A to form a cyclin A/CDK2
complex [16] to continue the cell cycle. Cyclin B
binds to Cdc2 (CDK1) during cell division to control
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cell entry and termination of mitosis. Cyclin B is
broken down when cell division is terminated and
enters another cycle [16].
In recent years, studies have found that two protein families, KIP and INK4, can inhibit the activity
of CDK, which is called CKI (CDK inhibitory protein), and KIP (kinase inhibitory protein) family includes: p21, p27, and p57. Inactivating it, if KIP is
expressed in excess, the cells will stay in the G1
phase, and P53 can induce p21 to generate [22]. It
has also been found that increased expression of p21
can cause cells to be quiescent in the S phase [23].
P27, on the other hand, inhibits the activity of cyclin/
CDK in the G1 phase [24] and binds to cyclin A/
CDK2 [25], resulting in cell cycle quiescence.
By inhibiting speciﬁc pathways, cells repair or
inspect the condition of the cell itself and changes in
the surrounding external environment. For example,
if the cell cannot perform repair work, it will inhibit
the activity of CDK and cyclin through CKI, stop the
cell cycle, or go to apoptosis [26]. In order to avoid
the occurrence of cell mutation or cancer caused by
the transmission of wrong information of cells [27],
this mechanism can be developed as a method for
cancer treatment alone or as an adjuvant.

2. Materials and methods
2.1. Plant identiﬁcation and crude extract from
Desmodium gangeticum (L.) DC. (Abbreviated as
DG)
D. gangeticum (L.) DC. was collected from middle
Taiwan, and plant identiﬁcation was performed by
Dr. Yung-Chung Hsieh, Department of Pharmaceutical Sciences and Chinese Medicine Resources,
China Medical University. Added 10 L of distilled
water into dried leaves and stems of D. gangeticum,
the extracts were collected (500 g), boiled, and
steamed to the concentrate of 300 ml, and ﬁltered
the concentrate with a 0.22 mm ﬁlter membrane to
get the ﬁnal extract. The extract was evaporated to
dryness and its weight was 27g (DG). The yield rate
was 5.4%. DG was stored in a 80  C freezer until
use. Various concentrations of DG (0.125e1 mg/ml)
were used to treat A549 cells.
2.2. Chemicals and reagents
RPMI-1640 cell culture medium, FBS (fetal bovine
serum), Penicillin/streptomycin (P/S), and trypan
blue were purchased from Gibco BRL, CA, USA.
Dimethyl sulfoxide (DMSO), Propidium iodide (PI),
Ribonuclease A (RNase A), Bovine serum albumin
(BSA), Ammonium persulfate (APS), 3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), Cellytic ™ cell lysis reagent, Triton X100 were from SigmaeAldrich Chemical company,
St. Louis, USA. NeNeN’-N’-Tetramethylenediamine (TEMED), Polyoxyethylenesorbitan monolaurate (Tween-20), trypran-EDTA, 40% acrylamide/
BIS- ACRYLAMIDE (29:1 Ratio), 10X Sodium
dodecylsulfate (SDS) buffer, Tris (tris(hydroxymethyl)-aminomethane), 10X SDS-PAGE running
buffer were from Amersco company, USA.
Apoptosis detection kit (PI/Annexin V-FITC) was
from Becton Dickinson, USA. Western lightning
chemiluminescene reagent plus (ECL) kit was from
NEN Life Science, USA. Anti-cyclin A (ab7956), anticyclin B1 (ab2949), anti-cyclin D1 (ab7958), anticyclin E (ab7959), anti-CDk1/Cdc2 (ab6537), antiCdk2 (ab7954), anti-Cdk4 (ab7955), Anti-Cdk6
(ab41870), Anti-p27K1P1 (ab47590), Anti-p21
(ab47452), goat anti-mouse IgG (HRP) horseradish
peroxide conjugated antibody were from Abcam
company, Cambridge, UK. b-actin (C4): sc-477778,
were from Santa Cruz biotechnology, CA, USA.

with DG (0.5 mg/ml, 1 mg/ml) for 24e72 h, the cells
were stained with FITC conjugated Annexin-V/PI.
The percentage of Annexin-V/PI stained cells was
determined by ﬂow cytometry. It was divided into a
quadrant: (Q1) necrotic cells, (Q2) late apoptotic cells,
(Q3) living cells, (Q4) early apoptotic cells.

2.3. Cell culture

IC50 values of DG were calculated by linear
approximation regression of the percentage survival
versus the drug concentration. The experiments
were performed at least in triplicate and all data
were expressed as the mean ± standard error. Student’s t-test and one-way ANOVA followed by
Dunnett’s test were used for single variable comparison and multiple variable comparisons, respectively. Signiﬁcance was considered when *P < 0.05.

A549 human lung cancer cell line was purchased
from the Bioresource Collection and Research
Center (BCRC) in Hsinchu, Taiwan. A549 cells were
maintained in RPMI-1640 medium containing
100 ml/L FBS and 100,000 U/L penicillin/100 mg/L
streptomycin.

2.6. Western blotting
A549 cells were plated onto 10-cm dishes and
treated with various concentrations of DG
(0.125e1 mg/ml) for 48 h. Total cell lysates were
prepared as previously described [13]. Forty mg of
total protein was applied to SDS-PAGE and transferred onto a polyvinylidene diﬂuoride (PVDF)
membrane. Then, the blots were incubated with the
appropriate dilution of speciﬁc monoclonal antibodies for cyclin E, cyclin A, CDK2, Cdc 2, p21, p27,
and Bcl-2. Protein expression was detected using
enhanced chemiluminescence kits (ECL kits) [28].
2.7. IC50 calculation and statistical analysis

2.4. Cell viability
A549 cells were plated onto 96-well plates and
incubated with various concentrations of DG
(0.125e1 mg/ml) for 24e72 h. MTT was added to
each well and incubated for another 1 h at 37  C,
then dissolved the blue formazan product in 200 ml
DMSO for 15 min, and the plates were read using a
spectrophotometric plate reader (Bio-Rad, Japan) at
O.D.570 nm.
2.5. Cell cycle distribution and apoptosis
determination
A549 cells were plated onto 12-well plates and
incubated with various concentrations of DG
(0.125e1 mg/ml) for 24e72 h. A549 cells were ﬁxed in
75% ethanol at 4  C for overnight and re-suspended in
1X PBS containing PI (40 mg/ml), RNase (0.1 mg/ml)
and Triton X-100 (0.1%) for 30 min. Cell cycle distribution and apoptosis determination were analyzed
by ﬂow cytometry (FACS Calibur, Becton Dickinson,
USA) as previously described [27]. After stimulation

3. Results
3.1. Effects of DG on the morphology, viability, and
apoptosis of A549 cells
A549 cells were treated with various concentrations of DG (0.125, 0.25, 0.5, 0.75, and 1 mg/ml) for
24 h, 48h, and 72h, respectively, and the cell viability
was detected by MTT tests and propidium iodide
staining. DG showed a concentration-dependent
and time-dependent inhibition on the morphology
and cell viability of A549 cells, *P < 0.05 and
**P < 0.01 as shown in Fig. 1. The IC50 of DG was
1.26 mg/ml, 0.93 mg/ml, and 0.82 mg/ml for 24, 48,
and 72 h, respectively. The cell viability of DGtreated A549 cells detected by propidium iodide
staining revealed that DG inhibited the cell viability
in a concentration-dependent manner by ﬂow
cytometry analysis (as shown in Fig. 2). DG treatment-induced A549 cells apoptosis. After DG
treatment, A549 cells were stained with FITC conjugated Annexin-V/PI, and the Annexin-V/PI

ORIGINAL ARTICLE

BioMedicine
2022;12(2):31e39

34

Y.-F. CHEN ET AL
DESMODIUM GANGETICUM TREAT LUNG CANCER

BioMedicine
2022;12(2):31e39

ORIGINAL ARTICLE
Fig. 1. After DG treatment, the morphology and viability change of A549 human lung cancer cells. (A) The morphology changes of A549 cells after
treatment with various DG concentrations (0.5 and 1 mg/ml) for 24, 48, and 72 h, respectively. (B) The viability of A549 was treated with various
concentrations of DG (0.125~1 mg/ml) for different time courses (24, 48, and 72 h) by MTT viability assay. DG showed a concentration-dependent
and time-dependent inhibition on the morphology and cell viability of A549 cells. (C) The IC 50 of DG at different time of treatment. Results
represented as mean ± S.E. *P < 0.05, **P < 0.01 was considered statistically signiﬁcant compared to the control group.

stained cells were determined by ﬂow cytometry.
DG showed a concentration-dependent and timedependent induction apoptosis of A549 human cells
as shown in Fig. 3.

accumulation (*P < 0.05 for 0.25-l and 0.5 mg/ml and
**P < 0.01 for 0.75 mg/ml) as shown in Fig. 4.
3.3. Effect of DG on the cell cycle-related proteins
of A549 cells

3.2. Effects of DG on the cell cycle of A549 cells
After various concentrations of DG (0.125e1 mg/
ml) treatment for different time courses (24e72 h),
the cell cycle of A549 cells was analyzed by ﬂow
cytometry. The DNA content of the cell cycle is
highest in the G1 phase, followed by the S phase,
and the G2/M phase is the least. Compared to the
control group, DG induced the G1 phase

After treatment with various concentrations of DG
(0.25e1 mg/ml) in A549 cells, DG increased the cell
population in G1. DG decreased the expression of
cyclin A, cyclin B1, and Cdc2 (CDK1) proteins related
to the S phase; and increased the expression of p21,
p27, cyclin D1, and cyclin E proteins related to the G1
phase of the cell cycle in A549 cancer cells in a concentration-dependent manner as shown in Fig. 5.
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Fig. 2. The cell viability of A549 cells treated with various concentrations of DG (0.125e2.0 mg/ml) for different time lengths. (A) The viability of
A549 cells treated with various concentrations of DG for 24, 48, 72h, respectively, by ﬂow cytometry. (B) The viability change and time course of
A549 cells treated with various concentrations of DG for 24 to 72h. A549 Cell viability was detected by propidium iodide staining and expressed as %
of control. DG inhibited the cell viability in a concentration-dependent manner by ﬂow cytometry analysis. Data were expressed as mean ± S.E.
*P < 0.05, **P < 0.01, and ***P < 0.001 was considered statistically signiﬁcant compared to the control group.

4. Discussion
This study showed that DG had a concentrationdependent inhibitory effect on the survival rate of

A549 human lung cancer cells. In cell morphology,
after DG treatment, the cell morphology, cell
membrane, and nucleus were ruptured.
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Fig. 3. DG treatment-induced A549 lung cancer cells apoptosis. (A) A549 cells were treated with various concentrations of DG (0.5, 1 mg/ml) for
different time courses (24h, 48h, and 72 h). After DG treatment, A549 cells were stained with FITC conjugated Annexin-V/PI. The percentage of
Annexin-V/PI stained cells was determined by ﬂow cytometry. It was divided into a quadrant: (Q1) necrotic cells, (Q2) late apoptosis cells, (Q3) living
cells, (Q4) early apoptotic cells. (B) Represented the FITC conjugated Annexin-V/PI positive cells in each quadrant. DG showed a concentration- and
time-dependent-induction of A549 cells apoptosis. Values are expressed as mean ± S.E. *P < 0.05, **P < 0.01 was considered statistically signiﬁcant
compared to the control group.

In the early stage of cell apoptosis, phosphatidylserine in the cell membrane is externalized to the
outside, one of the changes in early cell apoptosis.
Annexin V is a calcium-dependent phospholipidbinding protein with a high afﬁnity to phosphatidylserine. FITC is labeled on Annexin V, doublestained with PI, detected and analyzed by ﬂow
cytometry, distinguishing normal, necrotic, and
apoptotic cells [29,30]. The results showed that DG
also partially caused apoptosis in a concentrationdependent manner.
There is a very tight control mechanism in regulating the cell cycle. Different cyclins are produced
at speciﬁc times in the cell cycle and then broken
down at speciﬁc times [16]. Once a cell is damaged,
some cell cycle-related proteins will activate and
terminate the cell cycle and repair DNA to continue
DNA replication and cell division. If repair is still
impossible, cells will choose cell cycle quiescence,
apoptosis [27]. The results of this experiment were
analyzed by ﬂow cytometry. It was found that cells
in G0/G1 phase increased and decreased in the S
phase after DG treatment, indicating that DG can
induce the cell cycle of A549 human lung adenocarcinoma cells to arrested in the G1 phase.

The related regulatory protein cyclin regulates the
cell cycle from one stage to another. The substances
promoting the cell cycle are responsible for the
regulatory protein kinase cyclin-dependent kinases
(CDK) group. CDK is usually not activated. Instead,
cyclin/CDK complexes are formed before the cells
enter the next state. Different cyclins are produced
and then decomposed at speciﬁc times in the cell
cycle [16], so the operation of the cell cycle requires
the interaction of its related proteins to complete.
Different drugs will inhibit different cyclins and
make cells quiescent in different periods to inhibit
the growth of cancer cells. Cell cycle-speciﬁc drugs
such as antimetabolites are most cytotoxic in the S
phase, and bleomycin causes cell cycle quiescence
in the G2 phase. Vinca alkaloids quiescent in
metaphase (M), etoposide blocks the S/G2 phase of
the cell cycle. Mechlorethamine and cisplatin often
cause damage in the G1 and S phases of the cell
cycle [31]. After DG treatment, A549 cells terminated in the G1 phase. The expression of cyclin A
and Cyclin B1, cell cycle-related proteins, was
inhibited, whereas the expression levels of cyclin D1
and cyclin E increased. The KIP and INK4 family of
proteins can inhibit the activity of CDK, which is
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Fig. 4. Flow cytometric analysis of cell cycle in A549 lung cancer cells after various concentrations of DG (0.125~1 mg/ml) treatment for different
time courses (24~48 h). (A) The ﬂow cytometry charts of DG-treated A549 cells. DG increased the G1 phase and reduced the S phase concentration
and time-dependent. (B) Represented cell cycle distribution of control and DG-treated A549 cells as measured by propidium iodide staining of DNA at
24h, 48h, and 72 h, respectively. After treatment with various concentrations of DG (0.25~1 mg/ml) in A549 cells, DG increased the cell population in
G1. When *P < 0.05 or **P < 0.01 is regarded as statistical signiﬁcance in the proportion of cells in the G1 phase versus control cells.

Fig. 5. DG treatment for 48 h affected the protein expression of various cell cycle-related kinases in A549 lung cancer cells.
Various concentration of DG (0.25~1 mg/ml) was used. The expression of cyclin A, cyclin B1, and Cdc2 were decreased after
DG treatment; however, the expression of cyclin D1, cyclin E, p21, and p27 was increased after DG treatment.
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Fig. 6. The anti-lung cancer mechanism of DG on A549 human lung
cancer cells is proposed in this diagram. DG arrests cell cycle in the G1
phase via increasing protein expression of p21, p27, cyclin D1, and
cyclin E; whereas DG decreases the expression of cyclin A, cyclinB1,
and Cdc2, leading to apoptosis of A549 cells.

generally called CDK inhibitory protein (CKI). The
kinase inhibitory protein (KIP) family includes p21,
p27, and p53. P21 and p27 bind to the Cyclin/CDK
complex, making it inactive. When KIP is overexpressed, cells will stay in the G1 phase. It has also
been found that the expression of p21 can cause
cells to be quiescent in the S phase [23]. The increase of p27 will inhibit the activity of cyclin/CDK
in the G1 phase [24], and it will also bind to cyclin A/
CDK2 [24], making it impossible to continue the
operation of the cell cycle and inhibit cell growth.
This study revealed that the protein expression of
p21 and p27 increased with the increase of DG
concentration, inhibiting their growth and resulting
in the inactivity of the cell cycle of A549 lung
adenocarcinoma cells.

5. Conclusions
This experiment found that DG, a crude extract of
D. gangeticum, could inhibit the growth of A549
human lung adenocarcinoma cells. DG decreased
cyclin A, cyclin B1, and Cdc2 expression, whereas
increased p21 and p27 expression in a concentration-dependent manner, thus, leading to arrest of
the cell cycle in the G1phase as shown Fig. 6. Data
implies that there will be opportunities to develop
DG to an anticancer drug or adjuvant preparations
for other anticancer drugs in the future.
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